Last €51.53 EUR
Change Today +0.383 / 0.75%
Volume 0.0
DUL On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 2:20 AM 08/29/14 All times are local (Market data is delayed by at least 15 minutes).

alnylam pharmaceuticals inc (DUL) Snapshot

Open
€51.50
Previous Close
€51.15
Day High
€51.98
Day Low
€51.50
52 Week High
01/13/14 - €80.35
52 Week Low
04/29/14 - €35.00
Market Cap
3.9B
Average Volume 10 Days
71.9
EPS TTM
--
Shares Outstanding
76.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ALNYLAM PHARMACEUTICALS INC (DUL)

alnylam pharmaceuticals inc (DUL) Related Businessweek News

View More BusinessWeek News

alnylam pharmaceuticals inc (DUL) Details

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, is engaged in discovering, developing, and commercializing novel therapeutics based on RNA interference (RNAi). Its principal programs under clinical or pre-clinical development include ALN-TTR comprising ALN-TTR02 and ALN-TTRsc for the treatment of transthyretin-mediated amyloidosis; ALN-AT3 for the treatment of hemophilia and rare bleeding disorders; ALN-CC5 for the treatment of complement-mediated diseases; ALN-AS1 for the treatment of hepatic porphyrias; ALN-PCS for the treatment of hypercholesterolemia; ALN-AAT for the treatment of AAT deficiency liver disease; ALN-TMP for the treatment of beta-thalassemia and iron-overload disorders; ALN-ANG for the treatment of genetic forms of mixed hyperlipidemia and severe hypertriglyceridemia; and other programs. The company’s partner-based product development clinical and pre-clinical programs comprise ALN-RSV01 for the treatment of respiratory syncytial virus infection; ALN-VSP for the treatment of liver cancers; and ALN-HTT product candidate for the treatment of Huntington’s disease. It has strategic alliances and collaboration agreements with Genzyme Corporation; The Medicines Company; Kyowa Hakko Kirin Co., Ltd.; Cubist Pharmaceuticals, Inc.; Monsanto Company; Takeda Pharmaceutical Company Limited; F. Hoffmann-La Roche Ltd./Arrowhead Research Corporation; Isis Pharmaceuticals, Inc.; Novartis Pharma AG; the Massachusetts Institute of Technology; Tekmira Pharmaceuticals Corporation and Protiva Biotherapeutics, Inc.; The University of British Columbia; Acuitas Therapeutics Inc.; Biogen Idec Inc.; Ascletis BioScience Co., Ltd.; Medtronic, Inc.; and CHDI Foundation, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.

165 Employees
Last Reported Date: 02/20/14
Founded in 2002

alnylam pharmaceuticals inc (DUL) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: $669.5K
President and Chief Operating Officer
Total Annual Compensation: $500.0K
Principal Financial Officer, Principal Accoun...
Total Annual Compensation: $252.1K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $450.0K
Chief Business Officer and Senior Vice Presid...
Total Annual Compensation: $400.0K
Compensation as of Fiscal Year 2013.

alnylam pharmaceuticals inc (DUL) Key Developments

Alnylam Pharmaceuticals, Inc. - Special Call

To discuss the ALN-AAT for the treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

Alnylam Pharmaceuticals, Inc. Reports Unaudited Consolidated Financial Results for the Second Quarter Ended and Six Months June 30, 2014

Alnylam Pharmaceuticals, Inc. reported unaudited consolidated financial results for the second quarter ended and six months June 30, 2014. For the quarter, the company reported net revenues from collaborators of $7,295,000 against $8,687,000 a year ago. Loss from operations was $45,005,000 against $21,312,000 a year ago. Loss before income taxes was $44,389,000 against $21,053,000 a year ago. Net loss was $44,074,000 or $0.58 per basic and diluted share against $18,169,000 or $0.29 per basic and diluted share a year ago. Non-GAAP net loss was $47,964,000 or $0.63 per basic and diluted share against $18,169,000 or $0.29 per basic and diluted share a year ago. For the six months, the company reported net revenues from collaborators of $15,570,000 against $27,329,000 a year ago. Loss from operations was $314,069,000 against $31,116,000 a year ago. Loss before income taxes was $313,202,000 against $30,628,000 a year ago. Net loss was $295,017,000 or $4.11 per basic and diluted share against $27,182,000 or $0.45 per basic and diluted share a year ago. Non-GAAP net loss was $74,251,000 or $1.03 per basic and diluted share against $27,182,000 or $0.45 per basic and diluted share a year ago.

Alnylam Pharmaceuticals, Inc. - Special Call

To discuss about ALN-CC5, for the treatment of Complement-Mediated Diseases

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DUL:GR €51.53 EUR +0.383

DUL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Enzon Pharmaceuticals Inc $1.64 USD +0.08
Galena Biopharma Inc $2.36 USD -0.03
Prosensa Holding NV $9.10 USD -0.05
Regulus Therapeutics Inc $6.88 USD +0.08
Tekmira Pharmaceuticals Corp C$23.20 CAD +0.49
View Industry Companies
 

Industry Analysis

DUL

Industry Average

Valuation DUL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 149.2x
Price/Book 5.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 131.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALNYLAM PHARMACEUTICALS INC, please visit www.alnylam.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.